摘要 I am most honored to be asked to contribute to the Asian Journal of Urology (AJU).For many years Asian urologists and investigators have provided major contributions to Urology.I applaud and salute this great moment.This new Journal will serve the world in so many unique ways, and we are proud to be part of this most historical moment.
Abstract: I am most honored to be asked to contribute to the Asian Journal of Urology (AJU).For many years Asian urologists and investigators have provided major contributions to Urology.I applaud and salute this great moment.This new Journal will serve the world in so many unique ways, and we are proud to be part of this most historical moment.
Donald S. Coffey. Evolution: back to the future to understand and control prostate cancer[J]. Asian Journal of Urology, 2014, 1(1): 4-11.
Donald S. Coffey. Evolution: back to the future to understand and control prostate cancer. Asian Journal of Urology, 2014, 1(1): 4-11.
DeMarzo AM, Coffey DS, Nelson WG. New concepts in tissuespecificity for prostate cancer and benign prostatic hyperplasia.Urology 1999;53: 29-39.
[2]
Coffey DS. Similarities of prostate and breast cancer: evolution,diet and estrogens. Urology 2001; 57:31-8.
[3]
Coffey DS, Walsh PC. Clinical and experimental studies of benignprostatic hyperplasia.Urol Clin North Am 1990; 17: 461-75.
[4]
Prins GS, Jung MH, Vellanoweth RL, Chatterjee B, Roy AK. Agedependentexpression of the androgen receptor gene in the prostateand its implication in glandular differentiation and hyperplasia. DevGenet 1996;18: 99-106.
[5]
De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG,et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer2007; 7: 256-69.
[6]
Jäämaa S, Laiho M. Maintenance of genomic integrity after DNAdouble strand breaks in the human prostate and seminal vesicleepithelium: the best and the worst. Mol Oncol 2012; 6: 473-83.
[7]
Stoeckle MY, Hebert PD. Barcode of life. Sci Am 2008; 299: 82-6.
[8]
Gleick J. The information. New York, NY: Pantheon Books, 2011.
[9]
Scott TA, Arnold R, Petros JA. Mitochondrial cytochrome c oxidasesubunit 1 sequence variation in prostate cancer. Scientifica (Cairo)2012; 2012: 701810.
[10]
Gann PH, Deaton R, Amatya A, Mohnani M, Rueter EE, Yang Y,et al. Development of a nuclear morphometic signature for prostatecancer risk in negative biopsies.PLoS One 2013; 8: e9457.
[11]
Veltri RW, Christudass CS.Nuclear morphometry, epigenetic changesand clinical relevance in prostate cancer. Adv Exp Med Biol 2014;773:77-99.
[12]
Bista RK, Wang P, Bhargava R, Uttam S, Hartman DJ, Brand RE, etal. Nuclear nano-morphology markers of histologically normal cellsdetect the “field effect” of breast cancer. Breast Cancer Res Treat2012;135: 115-24.
[13]
Benson MC, Walsh PC. The application of flow cytometry to theassessment of tumor cell heterogeneity and the grading of humanprostatic cancer: preliminary results. J Urol 1986; 135: 1194-8.
[14]
Lowes LE, Goodale D, Keeney M, Allan AL. Image cytometryanalysis of circulating tumor cells. Methods Cell Biol 2011; 102:261-90.
[15]
Yang X, Shi C, Toing R, Qian W, Zhau HE, Want R, et al. Near IRheptamethine cyanine dye-mediated cancer imaging. Clin CancerRes 2010; 16:2833-44.
[16]
Yang X, Shao C, Wang R, Chu CY, Hu P, Master V, et al. Opticalimaging of kidney cancer with novel near infrared heptamethinecarbocyanine fluorescent dyes. J Urol 2013;189:702-10.
[17]
Shinohara DB, Vaghasia AM, Yu SH, Mak TN, Brüggeman H,Nelson WG, et al. A mouse model of chronic prostatic inflammationusing a human prostate cancer-derived isolate of Propionibacteriumacnes. Prostate 2013; 73:1007-15.
[18]
Nelson WG, DeMarzo AM, Yegnasubramanian S. The diet as acause of human prostate cancer. Cancer Treat Res 2014; 159: 51-68.
[19]
Sharma OP, Adlercreutz H, Strandberg JD, Zirkin BR, Coffey DS,Ewing LL. Soy of dietary source play a preventive role againstthe pathogenesis of prostatitis in rats. J Steroid Biochem Mol Biol1992; 43: 557-64.
[20]
Richman EL, Kenfield SA, Stampfer MJ, Giovannucci EL, ZeiselSH, Willett WC, et al. Choline intake and risk of lethal prostatecancer: incidence and survival. Am J Clin Nutr 2012; 96: 855-63.
[21]
Nakai Y, Nelson WG, De Marzo AM. The dietary charred meatcarcinogen 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine actsas both a tumor initiator and promoter in the rat ventral prostate.Cancer Res 2007; 67: 1378-84.
[22]
Coffey DS. Self-organization, complexity and chaos: the newbiology for medicine. Nat Med 1998; 4:882-5.
[23]
Chu GC, Chung LW. RANK-mediated signaling network and cancermetastasis. Cancer Metastasis Rev 2014; 33(2-3): 497-509.
[24]
Morello M, Minciacchi VR, de Candia P, Yang J, Posadas E, Kim H,et al. Large oncosomes mediate intercellular transfer of functionalmicroRNA. Cell Cycle 2013; 12: 3526-36.
[25]
Camacho DF, Pienta KJ. Disrupting the networks of cancer. ClinCancer Res 2012; 18: 2801-8.
[26]
Camacho DF, Pienta KJ. A multi-targeted approach to treating bonemetastases. Cancer Metastasis Rev 2014; 33(2-3): 545-53.
[27]
Ben-Jacob E, Coffey DS, Levine H. Bacterial survival strategiessuggest rethinking cancer cooperativity. Trends Microbiol 2012;20: 403-10.
[28]
Lu M, Jolly MK, Levine H, Onuchic JN, Ben-Jacob E. Micro-RNA based regulation of epithelial-hybrid-mesenchymal fatedetermination. Proc Natl Acad Sci USA 2013; 110: 18144-9.
[29]
Schmidt LJ,Tindall DJ. Androgen recetor: past, present and future.Curr Drug Targets 2013; 14: 401-7.
[30]
Coffey DS, Shimazaki J, Williams-Ashman HG. Polymerizationof deoxyribonucleotides in relation to androgen-induced prostaticgrowth. Arch Biochem Biophys 1968; 124: 184-98.
[31]
Takaha N, Hawkins AL, Griffin CA, Isaacs WB, Coffey DS. Highmobility group protein I(Y): a candidate architectural protein forchromosomal rearrangements in prostate cancer cells. Cancer Res2002; 62: 647-51.
[32]
Getzenberg RG, Coffey DS.Changing the energy habitat of thecancer cell in order to impact therapeutic resistance. Mol Pharm2011; 8: 2089-93.
[33]
Garcia-Schurmann M, Coffey DS. The concept of evolution in thepathogenesis and treatment of prostate cancer. Br J Urol 1997; 79Suppl. 2: 9-17.
[34]
Lupold SE, Hicke BJ, Lin Y, Coffey DS. Identification andcharacterization of nuclease-stabilized RNA molecules that bindhuman prostate cancer cells via the prostate-specific membraneantigen. Cancer Res 2002; 62: 4029-33.
[35]
Ni X, Castanares M, Mukherjee A, Lupold SE. Nucleic acidaptamers: clinical applications and promising new horizons. CurrMed Chem 2011; 18: 4206-14.
[36]
Ni X, Zhang Y, Ribas J, Chowdhury WH, Castanares M, Zhang Z, etal. Prostate-targeted radiosensitization via aptamer-shRNA chimerasin human tumor xenografts. J Clin Invest 2011; 121: 2383-90.
[37]
Coffey DS. The real final exam. Prostate 1999; 39: 323-5.
Christopher Hartman, Nikhil Gupta, David Leavitt, David Hoenig, Zeph Okeke, Arthur Smith. Advances in percutaneous stone surgery[J]. Asian Journal of Urology, 2015, 2(1): 26
-32
.
